Companies / Daiichi Sankyo
Daiichi Sankyo
CompanyDaiichi Sankyo is a global pharmaceutical company based in Japan. It was established in 2005 through the merger of Sankyo and Daiichi Pharmaceutical and is listed on the Tokyo Stock Exchange.
- Trials
- 318
- Recruiting
- 31
- Completed
- 220
- With results
- 120
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 3 | — | — | — | — | — | 3 |
| Phase 1 | 9 | — | 7 | 67 | 11 | 1 | — | — | — | 95 |
| Phase 1/2 | 5 | 2 | 2 | 7 | 4 | — | — | — | — | 20 |
| Phase 2 | 2 | — | 4 | 49 | 10 | 3 | — | — | — | 68 |
| Phase 2/3 | 2 | — | — | 2 | 1 | — | — | — | — | 5 |
| Phase 3 | 8 | 3 | 9 | 40 | 4 | — | — | — | — | 64 |
| Phase 4 | — | — | — | 25 | — | — | — | — | — | 25 |
| Not applicable | — | — | — | 2 | — | — | — | — | — | 2 |
| Unknown | 5 | — | 2 | 25 | — | — | 1 | 1 | 2 | 36 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | — | 6 | 4 | 7 | — | 6 | — | — | 5 | 28 |
| Diabetes Mellitus, Type 2 | — | 3 | — | 4 | 1 | 10 | 3 | — | 1 | 22 |
| Hypertension | — | 2 | — | 1 | 1 | 3 | 11 | — | — | 18 |
| Neoplasm Metastasis | — | 7 | 2 | 4 | — | 2 | — | — | 1 | 16 |
| Leukemia, Myeloid, Acute | — | 7 | 2 | 3 | — | 3 | — | — | — | 15 |
| Breast Neoplasms | — | 2 | 2 | 3 | — | 5 | — | — | 2 | 14 |
| Recurrence | — | 7 | 3 | 2 | — | — | — | — | 1 | 13 |
| Neoplasms | — | 6 | 3 | — | — | 3 | — | — | — | 12 |
| Colorectal Neoplasms | — | 3 | 2 | 6 | — | — | — | — | — | 11 |
| Ovarian Neoplasms | — | 1 | 2 | 3 | 1 | 2 | — | — | 1 | 10 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Daiichi Sankyo | 318 | 69 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | AstraZeneca | 25 |
| 2 | Merck Sharp & Dohme LLC | 25 |
| 3 | Plexxikon | 9 |
| 4 | Daiichi Sankyo Co., Ltd. | 8 |
| 5 | Syneos Health | 5 |
| 6 | Ambit Biosciences Corporation | 3 |
| 7 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 3 |
| 8 | Daiichi Sankyo Korea Co., Ltd. | 3 |
| 9 | Medpace, Inc. | 3 |
| 10 | Bristol-Myers Squibb | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | trastuzumab deruxtecan | 26 |
| 2 | Olmesartan Medoxomil | 24 |
| 3 | edoxaban | 21 |
| 4 | quizartinib | 18 |
| 5 | pexidartinib | 16 |
| 6 | Colesevelam Hydrochloride | 15 |
| 7 | Hydrochlorothiazide | 14 |
| 8 | exatecan | 13 |
| 9 | Paclitaxel | 11 |
| 10 | Amlodipine | 10 |
Evidence
- Results reported
- 54.5%120 of 220 completed
- Published
- 5.5%12 of 220 completed
- Primary endpoint met
- 58.2%96 of 165 analyses
- Median months to report
- 18
Documents disclosed
Trial profile
- Median enrollment
- 129
- Median duration
- 26months
- Countries
- 69
- Study sites
- 8742
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 18
- Phase 1
- 40
- Phase 1/2
- 127
- Phase 2
- 117
- Phase 2/3
- 630
- Phase 3
- 560
- Phase 4
- 129
- Not applicable
- 643
- Unknown
- 835
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 84 |
| 2 | Houston | United States | 79 |
| 3 | Los Angeles | United States | 71 |
| 4 | San Antonio | United States | 68 |
| 5 | Barcelona | Spain | 67 |
| 6 | Boston | United States | 62 |
| 7 | Madrid | Spain | 62 |
| 8 | Chicago | United States | 60 |
| 9 | Nashville | United States | 59 |
| 10 | Dallas | United States | 57 |
Terminations
- Terminated
- 30
- Withdrawn
- 4
- Stopped for recruitment
- 0.3%1 of 318 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05394675 Terminated | Terminated | It was Daiichi Sankyo, Inc.'s decision to discontinue further internal development of DS-9606a | 2026-02-06 |
| NCT05979831 Terminated | Terminated | The study was terminated based on a business decision by the Sponsor. | 2025-01-06 |
| NCT03248492 Terminated | Terminated | The last participant was transitioned to alternative study. | 2024-05-06 |
| NCT03505710 Terminated | Terminated | Last participant transitioned to alternative study. | 2024-04-17 |
| NCT04276415 Terminated | Terminated | The study was terminated due to a business decision. | 2022-03-11 |
| NCT04479436 Terminated | Terminated | Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study. | 2022-02-03 |
| NCT03552029 Terminated | Terminated | This study was terminated based on a business decision by the Sponsor. | 2021-04-01 |
| NCT03110354 Terminated | Terminated | This study was terminated due to slow accrual. | 2021-03-09 |
| NCT03255083 Terminated | Terminated | This study was terminated based on a business decision by the Sponsor. | 2020-09-04 |
| NCT02319369 Terminated | Terminated | This study was terminated based on a business decision by the Sponsor. | 2020-08-21 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: